Uloric Lawsuits Involving Heart Attacks And Strokes Follow Recent FDA Warnings About Cardiovascular Deaths

February 2019 Uloric Label Changes Include New "Black-Box Warning" To The Effect That Uloric Is Gout Drug Of Last Resort   (Posted by Tom Lamb at DrugInjuryWatch.com)   As a result of recent FDA-mandated label changes for Uloric there have been lawsuits filed against Takeda Pharmaceuticals America, Inc., the manufacturer of Uloric. Those drug injury lawsuits allege that the drug company Takeda failed to warn Uloric users about the increased risks of heart attacks and strokes. Uloric (febuxostat) tablets have been generally prescribed for the management of chronic gout since 2009. In March 2019 we posted this article, "Uloric 'Black-Box Warning' For Increased Risks Of Heart-Related Deaths And Cardiovascular Side Effects". This earlier article explained that while there was no Uloric recall ordered, in February 2019 the FDA required its strongest safety warning, i.e., Bolded Warning or Black-Box Warning, for the Uloric drug label to inform…

Read more detail on Recent Products Liability posts –

This entry was posted in Products Liability and tagged , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply